AstraZeneca


Robust Q1; well-poised for further acceleration

03/05/21 -"Astra kicked-off 2021 on a promising note, from both a sales and profitability perspective. Besides a healthy (though somewhat slower) performance for the lynchpin oncology portfolio, the strong ..."

Pages
79
Language
English
Published on
03/05/21
You may also be interested by these reports :
07/05/21
Benefiting from the strong uptake of the subcutaneous formulation and continued market share gain across lines, Darzalex reported ...

06/05/21
Benefiting from the strong uptake of the subcutaneous formulation and continued market share gain across lines, Darzalex reported ...

05/05/21
2021 started on a high as Novo reported robust growth, despite ‘tough comps’, i.e. forward buying-driven Q1 20. Moreover, as management expects this ...

05/05/21
Merck’s preliminary figures came in a bit out of the blue, but street expectations were too moderate (adjusted EBITDA: -15%). We were more positive, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO